Metrics to compare | 298380 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship298380PeersSector | |
|---|---|---|---|---|
P/E Ratio | −196.2x | −36.6x | −0.5x | |
PEG Ratio | −5.37 | 0.00 | 0.00 | |
Price/Book | 47.9x | 2.5x | 2.6x | |
Price / LTM Sales | 93.5x | 20.0x | 3.3x | |
Upside (Analyst Target) | 96.2% | 5.1% | 47.1% | |
Fair Value Upside | Unlock | −5.9% | 6.2% | Unlock |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.